Entegris, Inc. (ENTG) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 29, 2025. Entegris, Inc. is a leading supplier of critical advanced materials and process solutions for the semiconductor and high-technology industries. The company operates through two segments: Materials Solutions (MS) and Advanced Purity Solutions (APS). As of May 2, 2025, there were 151.4 million shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Sales | $773.2 million | $771.0 million |
| Gross Profit | $356.5 million | $351.8 million |
| Gross Margin | 46.1% | 45.6% |
| Operating Income | $122.3 million | $117.6 million |
| Net Income | $62.9 million | $45.3 million |
| Diluted EPS | $0.41 | $0.30 |
| Operating Cash Flow | $140.4 million | $147.2 million |
| Total Debt (Net) | $3,984.5 million | $3,981.1 million |
| Cash and Equivalents | $340.9 million | $329.2 million |
Material Changes vs. Prior Period
- Revenue Stability: Net sales were flat year-over-year. A $41.5 million increase driven by semiconductor market demand was offset by a $33.9 million decrease due to the prior-year divestiture of the Pipeline and Industrial Materials (PIM) business and a $5.4 million reduction from unfavorable foreign currency translation.
- Profitability Improvement: Net income increased 39% to $62.9 million. This was driven by higher gross profit (improved plant performance) and lower interest expense, despite a 18% increase in Engineering, Research, and Development (ER&D) expenses to $84.8 million.
- Segment Performance:
- Materials Solutions (MS): Sales decreased 2% to $341.4 million due to the PIM divestiture, but segment profit rose 12% to $75.0 million, aided by the absence of a $13.0 million impairment charge recorded in Q1 2024.
- Advanced Purity Solutions (APS): Sales increased 3% to $433.9 million due to higher demand for gas purification and filtration products. Segment profit declined 3% to $108.1 million due to unfavorable product mix.
- Capital Expenditures: Increased significantly to $108.0 million from $66.6 million in the prior year, reflecting continued investment in capacity.
Outlook, Risks, and Unusual Items
- Government Grants: On December 3, 2024, Entegris entered an agreement to receive up to $77.0 million under the CHIPS and Science Act for a manufacturing facility in Colorado Springs. No disbursements had been received as of March 29, 2025.
- Dividends: The board declared a quarterly cash dividend of $0.10 per share, payable May 21, 2025.
- Trade Risks: Management highlighted significant risks related to U.S. tariffs and retaliatory measures from countries like China. These actions may increase sourcing costs, force price increases, and reduce demand for products sold in China.
- Unusual Items: Q1 2024 included a $13.0 million long-lived asset impairment charge and a $4.8 million gain on the sale of the PIM business, neither of which occurred in Q1 2025. Q1 2025 included $2.4 million in restructuring costs.
Investor Verification Checklist
- CHIPS Act Funding: Verify the timeline for the first disbursement of the $77.0 million grant and associated milestones.
- China Exposure: Assess the specific impact of new tariffs on the 20% of revenue generated from China and potential supply chain disruptions.
- ER&D Spend: Monitor the sustainability of the increased ER&D spending ($84.8M) and its impact on future product launches.
- Debt Maturities: Review the debt schedule, noting $400 million due in 2028 and $2.75 billion due in 2029, against current cash flow generation.
- Non-GAAP Reconciliation: Review the reconciliation of GAAP Net Income to Non-GAAP EPS ($0.67) to understand the impact of excluded items like amortization and restructuring.